Want to see IMVT full AI Analyst Report?
IMVT Stock Chart & Stats
$39.41
$0.83(2.11%)
At close: 4:00 PM EDT
$39.41
$0.83(2.11%)
Day’s Range― - ―
52-Week Range$14.47 - $42.92
Previous CloseN/A
Volume269.94K
Average Volume (3M)1.35M
Market Cap
$8.64B
Enterprise Value$7.12K
Total Cash (Recent Filing)$797.80M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Oct 30, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.82
Shares Outstanding206,552,690
10 Day Avg. Volume843,308
30 Day Avg. Volume1,347,835
Financial Highlights & Ratios
PEG Ratio-6.12
Price to Book (P/B)5.31
Price to Sales (P/S)0.00
P/FCF Ratio-11.12
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$51.27Price Target Upside30.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.87
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And Near-zero DebtNear-zero debt and sizable equity provide durable financial flexibility, reducing refinancing and interest-rate risk. This balance-sheet strength underpins sustained R&D investment and trial funding, lengthening runway and lowering the probability that programs are cut for lack of capital.
Diversified Pipeline With Multiple Near-term CatalystsA broad, multi-indication development program spreads binary risk across assets and geographies. Multiple readouts and potential approvals over the next 2–3 years increase the chance at least one program reaches commercialization, supporting long-term business viability beyond any single trial outcome.
Material Settlement Significantly Boosted LiquidityThe settlement materially expands cash reserves, extending runway and enabling continued registrational studies, commercialization planning, and selective capital returns without near-term dilutive financing. This materially lowers funding risk while the company advances multiple late-stage programs.
Bears Say
Pre-revenue Status With Widening Net LossesSustained pre-revenue operations and growing net losses mean the company depends on cash reserves or external financing to sustain development. Persistent negative returns on equity and no commercial cash inflows increase dilution and execution risk until one or more programs generate revenue.
Very High Cash Burn And Deeply Negative Operating Cash FlowLarge, persistent cash outflows erode liquidity over time and can force reprioritization of programs or capital raises if not offset by non-dilutive events. Even with recent proceeds, sustained high burn raises longer-term funding needs tied to execution of multiple Phase III programs and commercialization buildouts.
Material Clinical And Translation Risks Across ProgramsPlacebo variability, uncertain translation between indications, and safety class perceptions are structural trial risks that can require larger samples, lead to failed pivotal studies, or delay approvals. These factors directly threaten the probability and timing of future commercial revenues.
Immunovant News
IMVT FAQ
What was Immunovant, Inc.’s price range in the past 12 months?
Immunovant, Inc. lowest stock price was $14.47 and its highest was $42.92 in the past 12 months.
What is Immunovant, Inc.’s market cap?
Immunovant, Inc.’s market cap is $8.64B.
When is Immunovant, Inc.’s upcoming earnings report date?
Immunovant, Inc.’s upcoming earnings report date is Oct 30, 2026 which is in 75 days.
How were Immunovant, Inc.’s earnings last quarter?
Immunovant, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.629 by -$0.121.
Is Immunovant, Inc. overvalued?
According to Wall Street analysts Immunovant, Inc.’s price is currently Undervalued.
Does Immunovant, Inc. pay dividends?
Immunovant, Inc. does not currently pay dividends.
What is Immunovant, Inc.’s EPS estimate?
Immunovant, Inc.’s EPS estimate is -0.72.
How many shares outstanding does Immunovant, Inc. have?
Immunovant, Inc. has 206,552,690 shares outstanding.
What happened to Immunovant, Inc.’s price movement after its last earnings report?
Immunovant, Inc. reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.629. Following the earnings report the stock price went up 1.171%.
Which hedge fund is a major shareholder of Immunovant, Inc.?
Currently, no hedge funds are holding shares in IMVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunovant Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.27 (30.10% Upside)
$51.27 (30.10% Upside)
Blogger Sentiment
Bullish
IMVT Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
115.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
28.88%
Trailing 12-Months
Company Description
Immunovant, Inc.
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
IMVT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial near-term and medium-term upside: a large multipart settlement that materially increases liquidity, an active and well-funded pipeline with multiple imminent readouts and a potential approval/launch for brexpiprazole in dermatomyositis, successful enrollments in registrational studies, and ongoing shareholder capital returns. These positives were balanced against recognized clinical and operational risks—placebo variability, translation risk for PH-ILD, JAK-class safety perceptions, geographic variability in trials, and continued high R&D and G&A spend. On balance, management presents confident execution and a strong catalyst calendar that outweigh the disclosed risks.View all IMVT earnings summariesIMVT Stock 12 Month Forecast
Average Price Target
$51.27
▲(30.10% Upside)
Technical Analysis
TG Therapeutics
―
Viridian Therapeutics
―
Aurinia Pharmaceuticals
―
Protagonist Therapeutics
―
Kymera Therapeutics
―
Ownership Overview
56.19% Insiders
11.94% Mutual Funds
4.30% Other Institutional Investors
20.00% Public Companies and
Individual Investors